## Highlights of This Issue 2721
### SPECIAL FEATURES

#### CCR Translations

2723  **Metformin and Pancreatic Cancer: A Clue Requiring Investigation**  
Michael Pollak  
See article p. 2905

#### Molecular Pathways

2726  **Molecular Pathways: Vasculogenic Mimicry in Tumor Cells: Diagnostic and Therapeutic Implications**  
Dawn A. Kirschmann, Elisabeth A. Seftor, Katharine M. Hardy, Richard E.B. Seftor, and Mary J.C. Hendrix

#### CCR Focus

2734  **Progress in Pediatric Cancer**  
Susan E. Bates

2735  **Genetically InFormed Therapies—A "GIFT" for Children with Cancer**  
Carol J. Thiele and Susan L. Cohn

2740  **Promising Therapeutic Targets in Neuroblastoma**  
Katherine K. Matthay, Rani E. George, and Alice L. Yu

2754  **Advances in the Genetics of High-Risk Childhood B-Progenitor Acute Lymphoblastic Leukemia and Juvenile Myelomonocytic Leukemia: Implications for Therapy**  
Mignon L. Loh and Charles G. Mullighan

2768  **Epigenetic Changes in Pediatric Solid Tumors: Promising New Targets**  
Elizabeth R. Lawlor and Carol J. Thiele

2780  **The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer**  
Daniel W. Lee, David M. Barrett, Crystal Mackall, Rimas Orentas, and Stephan A. Grupp

2791  **Using Germline Genomics to Individualize Pediatric Cancer Treatments**  
Navin Pinto, Susan L. Cohn, and M. Eileen Dolan

### Perspective

2801  **Disrupting the Networks of Cancer**  
Daniel F. Camacho and Kenneth J. Pienta

### Review

2809  **Pharmacogenomics in Early-Phase Oncology Clinical Trials: Is There a Sweet Spot in Phase II?**  
Peter H. O'Donnell and Walter M. Stadler

### HUMAN CANCER BIOLOGY

2817  **Suppression of Skeletal Muscle Turnover in Cancer Cachexia: Evidence from the Transcriptome in Sequential Human Muscle Biopsies**  

2828  **MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma**  
Molecular Profiling of Pancreatic Neuroendocrine Tumors in Sporadic and Von Hippel-Lindau Patients

Daniela Speisky, Aurélie Duces, Pascal Hammel, Alain Sauvanet, Stéphane Richard, Pierre Bedossa, Michel Vidaud, Arnaud Murat, Patricia Niccoli, Jean-Yves Scouace, Philippe Ruszniewski, and Anne Couvelard for the GTE Group (Groupe d’Étude des Tumeurs Endocrines)

CANCER THERAPY: PRECLINICAL

Lyn Kinase Mediates Cell Motility and Tumor Growth in EGFRvIII-Expressing Head and Neck Cancer

Sarah E. Wheeler, Elena M. Morariu, Joseph S. Bednash, Charlton G. Otte, Raja R. Seethala, Simion I. Chiosea, and Jennifer R. Grandis

L-BLP25 Vaccine plus Letrozole Induces a Th1 Immune Response and Has Additive Antitumor Activity in MUC1-Expressing Mammary Tumors in Mice

Neelima R. Mehta, Gregory T. Wurz, Rebekah A. Burich, Brittany E. Greenberg, Stephen Griffey, Audrey Gutierrez, Katie E. Bell, Jamie L. McCall, Michael Wolf, and Michael DeGregorio

IMAGING, DIAGNOSIS, PROGNOSIS

Tumor Infiltrating Immune Cells and Outcome of Merkel Cell Carcinoma: A Population-Based Study

Harri Sihto, Tom Böhling, Heli Kavola, Virve Koljonen, Marko Salmi, Sirpa Jalkanen, and Heikki Joensuu

Global Methylation Profiling for Risk Prediction of Prostate Cancer

Saswati Mahapatra, Eric W. Klee, Charles Y.F. Young, Zhifu Sun, Rafael E. Jimenez, George G. Klee, Donald J. Tindall, and Krishna Vanaja Donkena

Correlation of ERG Expression and DNA Methylation Biomarkers with Adverse Clinico-pathologic Features of Prostate Cancer

Ken Kron, Liyong Liu, Dominique Trudel, Vaijayantii Pethy, John Trachtenberg, Neil Fleschner, Bharati Bapat, and Theodoros van der Kwast

CANCER THERAPY: CLINICAL

Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer

Navid Sadeghi, James L. Abbruzzese, Sai-Ching J. Yeung, Manal Hassan, and Donghui Li

See commentary p. 2723

Pharmacokinetics and Repolarization Effects of Intravenous and Transdermal Granisetron

Jay W. Mason, Daniel S. Selness, Thomas E. Moon, Bridget O’Mahony, Peter Donachie, and Julian Howell

Survival of 1,181 Patients in a Phase 1 Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience

Jennifer Wheleer, Apostolos V. Tsimberidou, David Hong, Aung Naing, Gerald Falchook, Sarina Piha-Paul, Siqing Fu, Stacy Moulder, Betzy Stephen, Sijin Wen, and Razelle Kurzrock

Microarray Analysis Verifies Two Distinct Phenotypes of Glioblastomas Resistant to Antiangiogenic Therapy


Analysis of Spontaneous Tumor-Specific CD4 T-cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes: Potential Synergistic Effect with Chemotherapy Response

Yann Godet, Elizabeth Fabre, Magalis Dosset, Michele Lamuraglia, Emeline Levisonnois, Patrice Ravel, Nadine Benhamoua, Aurélie Cazes, François Le Pimpesc-Barthes, Beatrice Gaugier, Pierre Langlade-Demoyen, Xavier Pivot, Philippe Saas, Bernard Mailière, Eric Tartour, Christophe Borg, and Olivier Adotévi

Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432

Gender Influences the Class III and V β-Tubulin Ability to Predict Poor Outcome in Colorectal Cancer

Marisa Mariani, Gian Franco Zannoni, Stefano Sioletic, Steven Sieber, Candice Martino, Enrica Martinelli, Claudio Coco, Giovanni Scambia, Shohreh Shahabi, and Cristiano Ferlini

An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial

Florence de Fraipont, Guénaëlle Levallet, Christian Creveuil, Emmanuel Bergot, Michèle Beau-Faller, Mounia Mounawar, Nicolas Richard, Martine Antoine, Isabelle Rouquette, Marie-Christine Favrot, Didier Debieuvre, Denis Braun, Virginie Westeel, Elisabeth Quoix, Elisabeth Brambilla, Pierre Hainaut, Denis Moro-Sibilot, Franck Morin, Bernard Milleron, and Gérard Zalcman on behalf of the Intergroupe Francophone de Cancérologie Thoracique (IFCT)

Prognostic and Predictive Role of JWA and XRCC1 Expressions in Gastric Cancer

Shouyu Wang, Xuming Wu, Yansu Chen, Jianbing Zhang, Jingjing Ding, Yan Zhou, Song He, Yongfei Tan, Fulin Qiang, Jin Bai, Jinyan Zeng, Zhenghua Gong, Aiping Li, Gang Li, Oluf Dimitri Røe, and Jianwei Zhou

ABOUT THE COVER

Methylation of the tumor suppressor gene Ras association domain family 1A (RASSF1A) is an independent adverse prognostic factor in patients with early-stage non–small cell lung carcinoma treated in the phase III trial on perioperative chemotherapy, IFCT-0002. The cover image is a photomicrograph showing RASSF1A protein distribution in immortalized interphasic bronchial epithelial cells, HBEC3, using confocal microscopy. RASSF1A is stained in red (Alexa-fluo red-labeled secondary antibody). Nuclei are shown in light purple (DAPI). For details, see the article by de Fraipont and colleagues on page 2976 of this issue.
Clinical Cancer Research

18 (10)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/18/10

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.